SEC Form 4 · accession 0001193125-26-331061
KESTRA MEDICAL TECHNOLOGIES, LTD. · KMTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Traci S Umberger
Officer — See Remarks · Director
Period of report
Jul 30, 2026
Accepted (ET)
Aug 3, 2026 · 7:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001877184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jul 30, 2026 | S | 5,887 | $22.7437 | D | 215,747 | D | |
| Common SharesF3 | Jul 31, 2026 | S | 8,752 | $22.6048 | D | 206,995 | D | |
| Common SharesF4 | Aug 3, 2026 | S | 7,590 | $23.8553 | D | 199,405 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- F2The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2400 to $23.1700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F3The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F4The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6500 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Remarks
General Counsel and Chief Adminstrative Officer